

Case study

LASSA FEVER IN MAKURDI, NIGERIA: OUTCOMES DURING THE 2017/18 OUTBREAK

Abstract:-

Lassa Fever is a Viral Haemorrhagic Fever with yearly outbreaks in various parts of Nigeria over the past decade. The 2017/18 outbreak has been the worst recorded in the country and we wish to report a case series of the patients managed in Makurdi during the outbreak. All the patients had a history of fever with various symptoms suggestive of Viral Haemorrhagic Fevers and received intravenous ribavirin. One out of the four patients managed did not survive giving a case fatality rate of 25%.

Key Words:- Lassa virus, Lassa Fever, Makurdi, Outcomes

INTRODUCTION

Lassa fever is a viral haemorrhagic disease of global health concern. The disease is endemic in West Africa, and responsible for recurrent epidemics in parts of West Africa including Nigeria as well as sporadic distribution in Europe, Asia and America^{1,2}.

Lassa fever is zoonotic in nature. The multi-mammate rat, *Mastomys natalensis* has been known to be a natural host of the virus and rodent-human transmission frequently occurs among populations where the rats breed and humans are exposed to their secretions, droppings or eat the rats³. Human-human transmission also occurs especially in health care settings where proper barrier nursing and infection control practices are not maintained^{4,5}.

Deleted: :

Formatted: Font: Bold

Deleted: n

Deleted: of

Deleted: disease

Deleted: a

Deleted: infection

32 In Nigeria, there have been several outbreaks since 1969 when the virus was first
33 identified and named after the town (Lassa in Bornu state) where it was found⁶.
34 Since 1993, there have been almost yearly outbreaks mostly during the harmattan
35 season (November to March) especially in Edo state and environs and most of the
36 cases were managed at the Irrua Specialist Teaching Hospital, Edo state which is
37 the major diagnostic and treatment centre for Lassa Fever in the country⁶. The
38 2017/18 outbreak has been the worst so far as there were 431 laboratory-confirmed
39 cases in patients from 21 states with an estimated case fatality rate of 25%⁷.

40 We report a case-series of four patients managed for Lassa Fever at the Benue
41 State University Teaching Hospital, Makurdi during the 2017/18 outbreak
42 highlighting the challenges and outcome. This is to raise awareness about the
43 disease, improve surveillance and encourage all stakeholders in the health sector to
44 put in concerted efforts in preventing the disease and offer expertise care to anyone
45 infected with the virus.

46 CASE 1: Mrs AJ was a 30year old G₄P₃⁺⁰ trader who resided in Makurdi. She
47 presented to the Accident and Emergency unit of the hospital on account of
48 recurrent fever for 8 days and also headaches, epistaxis and jaundice for 4days. She
49 lived in a building with plenty of rats. She admitted to being pregnant though could
50 not remember the date of her Last Menstrual Period and was referred to the
51 Obstetrics and Gynaecology unit (O&G unit) who made an assessment of Viral
52 Hepatitis in a multigravida at 20 weeks. Her body temperature at presentation was
53 36.2°C. The Infectious Diseases Unit was subsequently invited and after their
54 review made a diagnosis of possible Lassa Fever in pregnancy and requested that
55 blood samples be sent to the research laboratory in Irrua for Lassa Virus
56 Polymerase Chain Reaction (PCR) which turned out to be positive (on the 4th day
57 of admission). FBC revealed marked neutrophil leukocytosis. Urinalysis revealed

Comment [OP1]: Check for misspelled and misused words.
Check and correct grammatical statement and typographical words.
All referred statement should be cited appropriately.

58 microscopic haematuria. She was afebrile throughout the period she was on
59 admission. IV ribavirin was commenced after the confirmatory test but her
60 condition kept deteriorating and she died on the 6th day of admission.

61 CASE 2: Mr GS, a 27year old commercial driver who lives in Zakibiam, about 180
62 km from Makurdi. He presented with fever and petechial rashes of 6 days duration.
63 He had a significant history of consumption of rats. Examination findings at
64 presentation revealed a temperature of 38.4°C, subconjunctival haemorrhage and
65 exudative pharyngitis. Blood samples sent to Irrua for Lassa PCR turned out to be
66 negative and Urinalysis revealed microscopic haematuria. He was commenced on
67 IV ribavirin after blood samples for Lassa virus PCR were collected and his
68 clinical condition improved steadily till discharge.

69 CASE 3: Mr AD, a 34year old male farmer who lives in Aliade about 60 Km from
70 Makurdi. He presented with a 2week history of recurrent fever and 4 day history of
71 frequent passage of loose stools. He was very fond of eating rats. He had taken
72 antimalarials and antibiotics with poor relief of the symptoms but it was the
73 diarrhoea that necessitated his presentation to the hospital. Examination findings at
74 presentation were unremarkable except for a temperature of 39.9°C. Urinalysis
75 revealed microscopic haematuria. He was suspected to have Lassa Fever and IV
76 ribavirin was commenced on the day of presentation with marked resolution of the
77 fever. However, samples for Lassa virus PCR which were collected after patient
78 commenced therapy turned out negative.

79

80 CASE 4: Miss KF, a 24year old nurse who also lives in Aliade. She presented with
81 a 10day history of recurrent fever and 3day history of yellowness of the eyes. She
82 had a habit of eating rats and also took antimalarials and antibiotics with poor

83 resolution of the symptoms but presented due to the jaundice. She had not made
84 contact with anyone with similar symptoms and viral screening for Hepatitis B and
85 C viruses were negative. Examination findings at presentation were a temperature
86 of 39.7°C and hepatomegaly. Urinalysis revealed microscopic haematuria and
87 bilirubinuria. She was subsequently managed for Lassa Fever with IV ribavirin
88 although the Lassa virus PCR results came out negative.

Comment [OP2]: Check and correct grammatical and typographical errors. Justify your whole work.

89 **DISCUSSION**

Deleted:

Formatted: Font: Bold

Deleted: :

90 Lassa fever has been a cause of significant morbidity and mortality especially in
91 West Africa as it accounts for an estimated 200,000 to 500,000 cases and 5000
92 deaths yearly in some West African countries, particularly in Nigeria, Sierra
93 Leone, Liberia and Republic of Guinea⁸. In Nigeria, the prevalence of antibodies to
94 the virus in Nigeria is 21%⁹ as compared to 8-22% in Sierra Leone¹⁰ and 4-55% in
95 Guinea¹¹. In the last 50 years, more than 28 states in Nigeria and the Federal
96 Capital Territory have experienced one or more outbreaks of Lassa fever⁶.

Deleted: The

97 The first documented case reports of Lassa Fever outbreak in Makurdi was during
98 the outbreak in 2013 by Achinge *et al*¹². The diagnosis was made at the Benue
99 State University Teaching Hospital, Makurdi when a physician presented with
100 fever and bleeding diathesis after managing a patient with similar features.
101 Eventually both patients died and massive sensitization about the disease was done
102 in various health facilities and communities across the state.

Formatted: Font: Italic

103 In Nigeria, the Irrua Specialist Teaching Hospital, Irrua which was built in 1993
104 has over the years managed most of the cases in Nigeria and is currently a
105 reference centre for the diagnosis and management of Lassa Fever. However, there
106 have been numerous suspected or confirmed cases of the disease which occur at
107 other states and such patients also need urgent and expertise care because delay in

111 treatment often has fatal consequences. Hence, the need for case notification and
112 documentation, compare treatment outcomes and ultimately harmonize Lassa
113 Fever management across all treatment centres in the country.

114 The case reports above reveal a lot of about the patients with Lassa Fever who
115 lived within the same geographical area. It is noteworthy that the only mortality
116 recorded was the case of Lassa Fever in pregnancy giving a Case Fatality ratio of
117 25% which was the same ratio obtained at Irrua during the 2017/18 outbreak⁷.

118 All the patients had a history of contact with and/or consumption of rats. The
119 consumption of rats has been an age long practice in most parts of Benue state as it
120 is a local delicacy. However, with the recurrent outbreaks of Lassa Fever, there has
121 been a lot of sensitization campaigns discouraging such practices although some
122 individuals still indulge in such practices. Rodent control and discouraging
123 consumption of rodents should be taken very seriously in the prevention of the
124 disease as transmission via rats has been shown here to be of great significance.

125 Although there was no case of human-to-human transmission in this case series, all
126 health workers should be trained and retrained periodically on Infection Prevention
127 and Control as a measure to curb the spread of infections, including Lassa Fever in
128 health care settings. As there is currently no vaccine for Lassa Fever, these
129 measures should be used optimally for disease prevention.

130 Secondly, all the patients had a history of fever and were febrile at presentation
131 with temperatures ranging between 38.4°C – 39.9°C, except the pregnant patient
132 who had hypothermia (36.2°C). The absence of fever in her was most likely as a
133 result of severe sepsis and her pregnant status which further compromised her
134 immune status with subsequent inability to mount enough immune response to
135 generate a fever.

136 It is noteworthy that all the patients presented after about a week of having fever
137 mostly because they felt they had malaria and were taking antimalarials at home.
138 Therefore, patients with recurrent febrile ailments should be encouraged to present
139 early to the hospital especially in Lassa fever endemic areas. This is to ensure
140 prompt evaluation as delay in diagnosis and commencement of ribavirin has been
141 responsible for most of the mortalities from Lassa Fever.

142 In addition to the fever, each patient had different symptoms such as bleeding
143 diathesis, jaundice, diarrhea and headache affecting various systems of the body
144 indicating that Lassa Fever is a multi-systemic disease. Hence, all health workers,
145 especially in endemic areas should be trained and re-trained periodically on the
146 management of the disease in all age groups including pregnant women for best
147 outcomes. Currently, there is a handbook by the Nigerian Center for Disease
148 Control and Prevention (NCDC) on Lassa Fever which contains essential
149 information for all cadres of health workers for ease of use. It is advised that copies
150 should be made available to every health facility especially in areas that are prone
151 to outbreaks.

152 Thirdly, all the patients had microscopic haematuria. Hence, urine testing for
153 haematuria in suspected Lassa Fever cases should be emphasized as this could be
154 an invaluable tool for Lassa Fever diagnosis in health facilities where confirmatory
155 PCR test cannot be done. There have also been previous reports of microscopic
156 and gross haematuria in patients with Lassa fever and clinicians should endeavour
157 to do urinalysis for all febrile patients especially during Lassa Fever epidemics.
158 Interestingly 3 of the patients tested negative to the Lassa virus PCR and there is
159 need for further investigations to determine factors that may be responsible such as
160 different strains of the virus or timing of sampling.

161

Comment [OP3]: Justify your work. Also make sure ALL similar studies are well cited. Check grammatical and syntax errors.

162 **CONCLUSION**

163 The recent (2017/18) Lassa Fever epidemic in Nigeria, which has been recorded to
164 be the worst, had some cases in Makurdi and rodent-to-human transmission was
165 mostly responsible. All efforts at rodent control, improving surveillance and
166 education of all health workers cadres as well as the general public about the
167 disease should be intensify for improved outcomes. Furthermore, early
168 presentation and commencement of ribavirin should be encouraged to enhance
169 outcomes.

170 **CONSENT:** All the patients gave their consent for the case reports.

171 **REFERENCES**

- 172 1. Monath TP. Lassa fever: review of epidemiology and epizootiology. Bull
173 World Health Organ 1975; 52:577–92.
- 174
- 175 2. Macher A, Wolfe M. Historical Lassa fever reports and 30-year clinical
176 update. Emerg Infect Dis 2006; 12:835–7.
- 177
- 178 3. Ogbu O, Ajuluchukwu E, Uneke CJ. Lassa fever in West African sub-
179 region: An overview. J Vect Borne Dis. 2007; 44:1–11.
- 180
- 181 4. Azeez-Akande O. A Review of lassa fever, an emerging old world
182 haemorrhagic viral disease in sub-saharan Africa. African J Clin Exp
183 Microbiol J Cln Exper Microbiol. 2016; 17:282–9.
- 184
- 185
- 186 5. Schmitz H, Köhler B, Laue T, Drosten C, Veldkamp PJ, Günther S, et al.
187 Monitoring of clinical and laboratory data in two cases of imported lassa
188 fever. Microbes Infect. 2002; 4:43–50.
- 189
- 190 6. Ogoina D. Lassa Fever: a clinical and epidemiological review. Niger Delta
191 Journal of Medicine and Medical Research 2013; 1:1-10.
- 192

Formatted: Font: Bold

Deleted: :

Deleted: of health workers

Deleted: ied

Deleted: for improved

Formatted: Font: Bold

Formatted: Font: Bold

Comment [OP4]: References should be done based on Journal format. Use mostly recent ones.

Formatted: Font: Bold

197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232

7. Siddle KJ, Eromon P, Barnes KG, Mehta S, Oguzie JU et al. Genomic Analysis of Lassa Virus during an Increase in Cases in Nigeria in 2018. *N Eng J Med*. 2018; 10.1056/NEJMoa1804498.
8. World Health Organization. Lassa fever. WHO fact sheet 2005. www.who.int
9. Tomori O, Fabiyi A, Sorungbe A, Smith A, McCormick JB. Viral hemorrhagic fever antibodies in Nigerian populations. *Am J Trop Med Hyg* 1988; 38:407–10.
10. McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES. A prospective study of the epidemiology and ecology of Lassa fever. *J Infect Dis* 1987; 155:437–44.
11. Bausch DG, Demby AH, Coulibaly M, Kanu J, Goba A, Bah A, et al. Lassa fever in Guinea: I. Epidemiology of human disease and clinical observations. *Vector Borne Zoonotic Dis* 2001; 1:269–81.
12. Achinge GI, Kur JT, Gyoh SK. Lassa fever Outbreak in Makurdi, North Central Nigeria: What you need to know. *Journal of Dental and Medical Sciences* 2013; 7: 42 – 6
13. Ajayi NA, Ukwaja KN, Ifebunandu NA, Nnabu R, Onwe FI et al. Lassa Fever- full recovery without ribavirin treatment: A case report. *African Health Sciences* 2014; 14: 1074 -7
14. Okokhere PO, Eramah CO, Alikah F, Akhideno PE, Iruolagbe CO et al. Acute Lassa Virus Encephalitis with Lassa Virus in the Cerebrospinal Fluid but Absent in the Blood: A Case Report with a Positive Outcome. *Case Rep Neurol* 2018; 10:150–158